Philip R. Reilly is a venture partner at Third Rock Ventures in Boston, Massachusetts. Trained in internal medicine and clinical genetics, he specializes in starting and launching companies to develop breakthrough therapies for heretofore untreatable genetic disorders. Among other roles, he has served on the boards of Edimer Pharmaceuticals and Lotus Tissue Repair, Inc. In 2010, he helped to found bluebird bio Inc., a gene therapy company; and from 2010 to 2012, he served as its chief medical officer. More recently, Reilly has been a founder of Voyager Therapeutics (which specializes in using the adeno-associated virus to treat disorders of the central nervous system) and Fulcrum Therapeutics, a company that focuses on gene regulation. Reilly holds an AB from Cornell University, a J.D. from Columbia University, and an MD from Yale University.

​

LinkedIn